Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Dec 1.
Published in final edited form as: Am J Med Genet A. 2024 Jul 29;194(12):e63827. doi: 10.1002/ajmg.a.63827

Gastrointestinal Manifestations in Williams Syndrome: A Prospective Analysis of an Adult and Pediatric Cohort

Michael Boechler 1,2,3, Yi-Ping Fu 4, Neelam Raja 5, Emily Ruiz-Escobar 5, Likitha Nimmagadda 5, Sharon Osgood 6, Mark D Levin 5, Colleen Hadigan 3, Beth A Kozel 5,*
PMCID: PMC11540717  NIHMSID: NIHMS2010249  PMID: 39073239

Abstract

Williams syndrome (WS) is a multi-system condition caused by the deletion of 25–27 coding genes on human chromosome 7. Irritability, gastrointestinal (GI) reflux and slow growth are commonly reported in infants with WS, but less data exist regarding GI concerns in older children and adults with the condition. This study evaluates 62 individuals with WS (31 children aged 3–17, and 31 adults aged 18–62) as well as 36 pediatric and adult controls to assess current and historical rates of common GI symptoms. Data were evaluated using a regression model including age, sex, self-reported race, and diagnosis. Symptoms including food intolerance, reflux, dysphagia, choking/gagging, vomiting, constipation, bloating, diarrhea, hematochezia, rectal prolapse, abdominal pain, and weight loss are more common in those with WS relative to controls. In addition, people with WS utilize more GI medications, specialty care, procedures, and supplemental feeds. Among those with WS, symptoms were present at similar rates in children and adults, except for diverticular disease, which was not noted until adulthood. GI symptoms are frequent in people with WS and serve as a significant source of morbidity.

Keywords: Williams Beuren syndrome, gastrointestinal symptoms, celiac disease, diverticular disease, healthcare utilization

Introduction

Williams Beuren syndrome (also known as Williams syndrome, WS) is a multisystem disorder caused by a deletion of part of chromosome 7. (Morris, 1993) The characteristic cardiovascular features of WS cause much of the associated morbidity and mortality; however, gastrointestinal (GI) symptoms impact quality of life and create stress for patients and caregivers. Previous multisystem reviews have noted GI complaints as part of a larger spectrum of features of the condition, (Kozel et al., 2021; Pober, 2010) but more granularity on symptoms is needed, especially outside of the neonatal period. While past human and mouse studies have suggested a possible role for ELN (Loffet et al., 2023) and BAZ1B, (Pai et al., 2024) as well as gut dysbiosis (Del Chierico et al., 2023) in the GI features of WS, improved classification of common GI complaints may enhance future genotype-phenotype correlation.

Methods

Participant Consent:

Individuals with WS and controls without WS were enrolled in a natural history study (Impact of Elastin Mediated Vascular Stiffness on End Organs study (clinical trial number: NCT02840448)) at the National Heart, Lung, and Blood Institute of the National Institutes of Health. Written informed consent was obtained from all participants or their parent, legal guardian, or authorized representative, as appropriate. Assent was obtained from cognitively capable individuals not providing consent. The study protocol was approved by the appropriate human subjects regulatory authority. Investigators adhered to the policies for protection of human subjects as prescribed in 45 Code of Federal Regulation 46.

Genetic evaluation:

All individuals with WS underwent molecular testing testing to confirm a diagnosis of WS and to assess deletion size. Participants were included in the analysis if their 7q11.23 deletion was confirmed to be the typical 1.5–1.8 MB deletion size in WS. Various modalities were used to assess deletion size (chromosomal microarray and genome sequencing with copy number analysis being most common details on deletion size determination can be found in Lugo et. al., 2021). Pediatric and adult controls reported being “healthy” at the time of recruitment and were chosen to represent the general population. Some were family members of those with WS. None carried a diagnosis of WS. No exclusions were made for common health conditions (e.g., hypertension, headache, mild depression), but the presence or absence of such conditions were noted. None reported recent hospitalizations or surgeries.

Standardized Interviews:

All participants and their caregivers (for children and those with WS) underwent a comprehensive standardized interview designed by CH reviewing their past and current GI health including characterization of symptoms, GI specialty care, medications and procedures conducted by one of two clinicians (CH and NR) with at least one visit between 2013 and 2022 using a standardized questionnaire. Participants were asked if they had ever experienced a list of GI symptoms and when the response was positive, follow-up questions were used to determine severity, duration, testing, treatments and current status of the symptom. Parents/caregivers, as well as individuals with WS, were included in the interviews. If an individual and their caregiver disagreed about a response, clarifying questions were asked to reach a unifying decision on the phenotype. For participants seen more than once, only data from the initial interview were analyzed. Additional medical records and research questionnaire data (assessed by LN and ERE) were used to supplement the history.

Analysis Plan:

After the review of the history with the patient and or family member, self-reported symptoms and conditions were scored as currently present, present in the past/resolved, or never present. Standardized diagnostic Rome IV criteria were used for assessment and characterization of GI symptoms where appropriate, such as constipation and bowel movements per week. We report the percentage of each group with current symptoms and those who “ever” had a symptom, where “ever” includes those with a current symptom and those with a resolved symptom. In addition to self-reported symptom of constipation, bowel movements per week was reported as a continuous variable. A detailed history of food intolerance, food allergy or food exclusion was solicited, but subjective gluten sensitivity or diagnosis of celiac disease was not specifically asked during each interview. Researchers reviewed cases of celiac disease and diverticulitis separately in external medical records and verified self-reported cases. Therefore, celiac disease and diverticulosis are presented separately from questionnaire data. Any discordance between patient responses and the medical record was resolved following clinician review (MB, BK, and CH).

Study personnel documented testing, procedures, and medication exposure history if it pertained to management or evaluation of a primary GI symptom. GI medications were defined as laxatives (PEG3350, saline/mineral oil enema, psyllium/lactulose, bisacodyl, senna, docusate, linaclotide, lubiprostone), anti-nausea medication (ondansetron, promethazine) motility agents (metoclopramide, loperamide, dicyclomine, hyoscyamine) and acid suppression (calcium carbonate, proton pump inhibitors, H2 receptor antagonists). History of antibiotic exposure was not elicited. GI testing/procedures included modified barium swallow, esophagogastroduodenoscopy (EGD), colonoscopy/flexible sigmoidoscopy, upper GI contrast study, rectal suction biopsy, pH probe impedance testing, contrast enema and gastric emptying studies.

Statistics:

For analysis, demographic characteristics were described as counts and percentages for categorical variables and as mean and standard deviation (SD) for continuous variables. T-test and Chi-square test were used to compare variables between WS cases and healthy controls. Multivariable logistic regression models adjusted for age, sex, and race (as reported by the participant) were used to evaluate the association between GI symptoms and WS status. All analyses were performed using SAS 9.4 (SAS institute, Cary NC). To account for multiple comparison, false discovery rate (FDR) adjusted p-values were calculated using Benjamini-Hochberg procedure, and those with FDR-adjusted p-value <0.05 were considered statistically significant.

Results

Sixty-six individuals with WS were evaluated by a gastroenterologist during the evaluation period. Four were excluded due to atypical deletion size, leaving 62 individuals (31 children and 31 adults) with typical 1.5–1.8 MB deletions in the WS region and 36 population controls (12 children and 24 adults) for further analysis. Demographic data for the two groups are presented in Table 1. Cases ranged from 3–62 years of age and included balanced representation of males and females (for all individuals, chromosomal sex was in cis with reported gender and sex assigned at birth). Cases and controls differed by age and self-reported racial background. All three variables were therefore used in the subsequent regression analyses. Symptom frequency for current symptoms is presented in Table 2, while the people who “ever” had a symptom are presented in Table 3, with a cartoon depicting the combined findings in Figure 1.

Table 1.

Demographic Characteristics of Participants with Williams Syndrome (WS) and Controls.

WS n=62 Control n=36 P-value
Age (years) Mean ± SD 20.63 ± 13.96 29.69 ± 16.75 4.98E-03
Sex at birth, n (%) Female 35 (56.5) 23 (63.9) 0.470
Male 27 (43.5) 13 (36.1)
Race, n (%) White 54 (87.1) 25 (69.4) 0.033
Non-white 8 (12.9) 11 (30.6)

Current Gastrointestinal Symptoms in Children and Adults with WS.

Table 2. Current Gastrointestinal (GI) Symptoms and Access to GI Care in Participants with WS and Controls.

Odds Ratio not shown for categories where one cohort is absent the symptom. Unadjusted p value shown for chi square test. Odds Ratio for the logistic regression and its p value is shown. Bold type denotes Benjamini-Hochberg Adjusted p-value <0.05.

Currently endorsing symptoms or care (%) Logistic Regression
adjusting for age, sex at birth and reported race
WS (n=62) Control (n=32) p value (Chi sq) Odds Ratio (95% CI) p value
Upper GI Symptoms
Food Intolerance 27.4% 13.9% 0.122 2.80 (0.84–9.35) 0.934
Reflux 24.2% 11.1% 0.114 6.01 (1.38–26.25) 0.017
Dysphagia 11.3% 0.0% 0.036 - -
Choking/Gagging 9.7% 2.8% 0.201 2.33 (0.25–21.39) 0.454
Vomiting 8.1% 2.8% 0.293 2.40 (0.25–23.19) 0.449
Odynophagia 1.6% 5.6% 0.275 0.21 (0.02–2.61) 0.224
Lower GI Symptoms
Constipation 48.4% 8.3% <0.0001 12.4 (3.09–49.7) 3.86E-04
Bloating 43.6% 13.9% 0.003 9.15 (2.49–33.61) 8.57E-04
Diarrhea 19.4% 5.6% 0.060 6.66 (1.19–37.34) 0.031
2° Incontinence Stool 12.9% 0.0% 0.025 - -
Hematochezia 6.5% 2.8% 0.426 4.13 (0.35–48.64) 0.260
Rectal Prolapse 6.5% 2.8% 0.426 2.39 (0.23–25.46) 0.469
GI Care
GI medications 48.4% 19.4% 0.004 13.26 (3.20–54.92) 3.64E-04
Specialty care 20.9% 5.6% 0.041 6.73 (1.23–36.84) 0.028
GI procedure(s) 19.4% 5.6% 0.060 4.61 (0.87–24.27) 0.072
Supplemental Feeds 4.8% 0.0% 0.180 - -
Other Conditions
Abdominal pain 38.7% 5.6% 0.0003 20.8 (3.58–120.98) 7.29E-04
Growth Failure 1.6% 0.0% 0.444 - -
Food Allergy 8.1% 5.6% 0.642 0.92 (0.15–5.74) 0.927
Weight Loss 8.1% 0.0% 0.080 - -

Table 3. Lifetime Gastrointestinal (GI) Symptoms and Access to GI Care in Participants with WS and Controls.

Unadjusted p value shown for chi square test. Odds Ratio for the logistic regression and its unadjusted p value is shown. Bold type denotes Benjamini-Hochberg Adjusted p-value <0.05. Odds Ratio not shown for categories where one cohort is absent the symptom. In addition, celiac was diagnosed in 4.8% of those with WS, and 0% controls (p-value 0.180) while diverticular disease was identified in 14.5% of those with WS and was not assessed in controls. Following the study, screening identified one additional participant from this cohort with celiac disease, for a total of 6.5% of the cohort.

Ever Endorsing Symptoms or Care (%) Logistic Regression
adjusting for age, sex at birth and reported race
WS (n=62) Control (n=32) p value (Chi sq) Odds Ratio (95% CI) p value
Upper GI Symptoms
Food intolerance 38.70% 13.90% 0.0095 4.76 (1.44–15.72) 0.0106
Reflux 69.4% 19.4% <0.0001 9.56 (3.22–28.42) 4.84E-05
Dysphagia 20.9% 0 0.0032 - -
Choking/Gagging 38.7% 2.8% <0.0001 17.28 (2.16–138.19) 7.22E-03
Vomiting 37.1% 5.6% 0.0006 9.51 (1.97–45.87) 5.05E-03
Odynophagia 4.80% 5.60% 0.876 0.56 (0.08–3.88) 0.560
Lower GI Symptoms
Constipation 61.3% 13.9% <0.0001 9.20 (2.95–28.65) 1.29E-04
Bloating 50.0% 16.7% 0.001 10.48 (2.91–37.82) 3.31E-04
Diarrhea 29.0% 11.1% 0.0404 6.45 (1.57–26.54) 9.87E-03
2° Incontinence Stool 17.7% 0.0% 0.0073 - -
Hematochezia 38.7% 8.3% 0.0012 7.56 (1.92–29.71) 3.79E-03
Rectal prolapse 24.2% 2.8% 0.0057 17.12 (1.87–156.55) 0.0119
GI Care
GI medications 74.20% 19.40% <0.0001 26.94 (6.75–107.52) 3.10E-06
GI subspecialty care 62.90% 8.30% <0.001 31.74 (6.89–146.17) 9.08E-06
GI procedure(s) 67.70% 19.40% <0.0001 35.40 (7.21–173.91) 9.08E-06
Supplemental feeds 29% 0.00% 0.0003 - -
Other Conditions
Abdominal pain 54.80% 5.60% <0.0001 28.37 (5.30–151.92) 9.32E-05
Growth failure 59.70% 0.00% <0.0001 - -
Food allergy 8.10% 5.60% 0.642 1.09 (0.17–6.82) 0.927
Weight loss 24.20% 2.80% 0.0057 18.34 (2.01–167.47) 0.00993
Neonatal jaundice 17.70% 2.80% 0.029 6.45 (0.72–57.65) 0.095
Hepatitis 3.20% 0.00% 0.276 - -
Gallbladder problems 1.60% 2.80% 0.694 0.75 (0.04–14.91) 0.849
Pancreatitis 1.60% 2.80% 0.694 0.57 (0.04–9.46) 0.698

Figure 1. Lifetime and Current Gastrointestinal (GI) Symptoms and Access to GI Care in Participants with WS and Controls.

Figure 1.

Only features with statistically significant p-value (<0.05) based on odds ratio are shown. For complete data, see Tables 2 and 3. Figure was created with Biorender.com.

Over all, individuals with WS reported higher rates of many GI symptoms and conditions relative to controls. There were no GI symptoms or complaints reported significantly more frequently by controls than by participants with WS. Constipation, bloating, GI medication use, and abdominal pain were the most reported “current” features, while reflux, constipation, growth failure, and abdominal pain were all reported as “ever” occurring in more than 50% of participants with WS. Bowel movements were reported at a rate of 8.78 +/− 4.86 (mean +/− SD) events per week in controls and 10.84 +/− 7.31 events in people with WS (p=0.0977).

After adjusting for age, sex and self-reported race, current reports of abdominal pain were 20.8 X (95% CI = 3.20–120.98 X) more likely in the WS cohort than in controls and constipation was 12.4 X (95% CI = 3.09–49.7 X) more likely. Liver and pancreatic-related conditions were uncommon and did not differ significantly between groups, either as current symptoms or historically, although a history of neonatal jaundice was recalled more often for members of the WS group.

Treatment of GI complaints was common, with 74% of WS participants reporting a history of GI medication use. Medications used by participants with WS at the time of study intake included those for gut motility (6/62, 9.7%), acid suppression (13/62, 21.0%), abdominal pain/discomfort (18/62, 29.0%), or constipation (22/62, 35.5%). Digestive supplements, such as probiotics, ginger, or garlic, were used by 12/62 people (19.4%). Additionally, more than 68% had undergone diagnostic GI testing and 63% were followed by a gastroenterologist at some point. The most frequent procedures were colonoscopy (12 individuals), upper GI imaging studies (10), and esophagogastroduodenoscopy (EGD) (9). Twenty-nine percent required supplemental feeds (defined as receipt of nasogastric or gastric-tube feeding or total parenteral nutrition for more than a few days) during their lifetime, but only two adult participants with WS reported a history of g-tube use in older childhood.

Celiac disease was identified in 3/62 patients (4.8%) at the time of structured interviews. One additional participant was identified after the interview portion of the study had been completed, bringing the total celiac diagnoses in the WS cohort to 4/62 (6.5%). No cases of celiac disease were present in the 36 control participants. No age specificity was identified. HLA genotype was not assessed.

After chart review and phone follow up with families, 9/31 (29%) adult individuals in the WS cohort had a history of diverticulosis. The youngest individual with WS and a history of diverticular disease had 30cm of colon resected at age 27 years after presenting with severe abdominal pain from perforated diverticulitis.

By separating the WS cohort into pediatric (3–17.9 years) and adult (18+ years) subgroups (Supplemental Table 1), we identified increased symptomatology in adults. Children with WS reported an average of 3.2 current symptoms (standard deviation (SD) 2.7), while adults with WS reported 4.9 current symptoms (SD 3.0, p<0.05). However, only diverticular disease reached statistical significance at the symptoms level. Concerns about stooling, certain foods, and vomiting/reflux are often chronic and cause significant distress in families.

Discussion

Our study presents the largest and most complete GI symptomatology report regarding individuals with WS published to date. Previous large WS cohort studies have focused on cardiovascular features without emphasis on GI features and those describing GI features have been generally smaller, more age-focused cohorts. (Cherniske et al., 2004; Morris et al., 1988) Our data add depth to available information on common symptoms and emphasizes rare and serious GI problems common to children and adults to WS. While our study did not objectively quantify the impact of GI symptoms on quality of life, in interviews it was apparent that GI problems were a consistent source of patient and family distress.

Natural history studies focusing on WS describe clinically significant vomiting in 40% (17/42), failure to thrive in 81% (34/42) and feeding difficulties in 71% (30/42) (Morris et al., 1988). Our study did not include infants and toddlers but did ask for recall for these symptoms across the lifespan. Our study showed that most symptoms endorsed by the group with WS were present in both children and adults, however the total number of symptoms was higher in adults than children. Diverticular disease was the only feature found to be statistically more common in adults at the symptom level.

Children with WS can present with feeding problems and later go on to have poor weight gain (Howlin & Udwin, 2006; Morris et al., 1988; Morris et al., 1990), leading to the development of WS specific growth charts (Morris et al., 2020). Reported growth failure in our cohort typically represented early life feeding difficulties and in some cases pre-dated WS diagnosis and use of appropriate growth charts. Adults with WS can also have considerable BMI variability, ranging from underweight to obesity (Renzi et al., 2023). Our data are consistent with prior reviews that conclude that people with WS rarely need a gastrostomy tube or long-term supplemental nutrition. (Morris et al., 2020)

Gastroenterology specialty care was common in this cohort. Likewise, more invasive interventions like esophagogastroduodenoscopy (EGD endoscopy) were common tools to evaluate reflux, dysphagia, and poor growth or as a prerequisite for referral to feeding therapy. Potential benefit of these procedures should be balanced with the 25–100 fold increased risk of sudden death with anesthesia seen in WS compared to non-WS age matched population. (Staudt & Eagle, 2021; Wessel et al., 2004) Any decision to perform endoscopy should be discussed with the patient’s cardiologist and performed in a setting with appropriate anesthesia expertise.

Stooling issues were common in both children and adults with WS (61.3% report ever having had had this symptom), with constipation being the most common issue. Self-reported rates of constipation were higher than the 50% and 43% historical prevalence reported in the WS American Academy of Pediatrics clinical practice guideline and earlier natural history studies. (Morris et al., 2020; Morris et al., 1988) Most people in our cohort reported at least daily bowel movements but many were receiving a stool softener or other treatment for constipation. There was also more secondary incontinence compared to controls, which may be related to stool burden, chronic constipation, and encopresis. Significant anxiety about stooling was a frequent theme during clinic interviews. Historically, a majority of adolescents and adults with WS have generalized or situational anxiety, with many of those receiving some sort of anxiolytic medication. (Pober, 2010)

There are many possible GI etiologies for abdominal pain commonly experienced by this cohort, including constipation, gas/bloating, acute illness, and changes in motility. (Morris et al., 1990) The differential for abdominal pain in those with WS should include ischemia and diverticulitis. Case reports describe perforated diverticulitis in people with WS as young as 9 years of age, (Ignacio et al., 2012) with other reports noting the condition in the second decade of life. (Deshpande et al., 2005; Garcia et al., 2009) Previous studies have diverticular disease in 8% of adults with WS (vs 2% non-WS). (Ignacio et al., 2012) In our cohort, diverticulosis was reported in 14.5% of the participants. This result is likely still an underestimate since colonoscopies are not routinely performed in young adults. Due to the potential associated serious morbidity and mortality, diverticular disease should be considered in the work up for abdominal pain even in younger people with WS.

Chronic constipation itself can change motility and lead to secondary colonic dilation, but abnormal dosage of WS genes ELN or BAZ1B may predispose to more severe disease. Studies in mice recently showed differences in the number of rectal ganglion cells and intralumenal air, but no motility differences in BAZ1B heterozygotes (Pai et al., 2024) Alternatively, decreased elastin may contribute to abnormal development of the embryonic mesentery (Loffet et al., 2023) or alter the mechanical properties of the colon, predisposing to over-stretching and mechanical tissue failure, contributing to diverticulosis. In the context of WS vascular insufficiency causing demand ischemia and pain should be considered. Vascular flow studies to investigate the mesenteric vasculature are ongoing by our group.

Gas and bloating, in addition to poor growth and diarrhea, can be presenting symptoms of celiac disease. Celiac disease was diagnosed in 4.8% of WS individuals in our cohort. We initiated screening in our clinic and an additional person from this cohort with WS had a positive TTG screen, potentially increasing this rate to 6.5% of the cohort evaluated. Worldwide prevalence of celiac disease is about 1.4% (Singh et al., 2018) but recent publications suggest an increased prevalence in WS. Estimates of celiac disease in WS vary between 1–2%, (Santer et al., 1996) to 10.8% (Ghisleni et al., 2023). In the latter, the affected individuals underwent HLA typing to assess genetic risk and were found to have similar rates of risk associated HLA-DQ2/DQ8 haplotypes (Ghisleni et al., 2023), suggesting the increased rate of celiac disease may not be attributed to genetic HLA risk alone.

The greatest limitation of our study is the inherent variability of perceived symptoms in survey responses. In addition, one of the characteristic features of WS is the desire to please. As such, it is possible that some people with WS may have answered in the affirmative to “help” investigators. To mitigate this, we have tried to be consistent in our data by using the same clinician to verify responses regarding symptoms. Including caregivers in the interview also mitigates some of the potential for inappropriate affirmative response. Another limitation may be recall bias of caregivers and patients. Further, healthy controls who are family members of persons with WS may have more familiarity with GI symptoms which may have biased their reporting. Our survey responses were broad ranging in the scope of possible GI symptoms, but do not include all possible GI symptoms. Quality of life impact may be inferred from the high frequency of requiring GI specialty care, procedures, and medications, but we were not able to objectively quantify the impact on quality of life, patient function (i.e., school attendance) and caregiver burden.

Conclusion

This descriptive study of a large cohort of individuals living with WS quantifies the most common and impactful GI symptoms for clinicians and caregivers. GI symptoms are common in people with WS of all ages. Those symptoms warrant evaluation and treatment when present. Certain treatable conditions, like celiac and diverticular disease may warrant specific screening in this population. Certain genes within the WS deleted region may predispose people with WS to particular phenotypes and GI conditions. Due to known concerns with anesthesia in this population, tests that require sedation should be discussed with the patient’s cardiologist. It is our hope that this is a useful guide in managing expectations for families and clinical practice guidelines for clinicians caring for patients with WS.

Supplementary Material

Supinfo

Funding Statement:

This work was funded by the Division of Intramural Research for the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Disease, and the Clinical Center of the National Institutes of Health.

Financial Disclosure:

The authors have no financial relationships relevant to this article to disclose.

Footnotes

Conflicts of Interest Disclosure: The authors declare no conflicts of interest.

Previous Presentations: None

Patient Consent: Written informed consent was obtained from all participants or their parent, legal guardian, or authorized representative, as appropriate. Assent was obtained from cognitively capable individuals.

Disclaimer: The views expressed in this article are those of the authors, and do not reflect the official policy or position Uniformed Services University of the Health Sciences, The United States Army, Department of Defense, or the U.S. Government.

Data Availability Statement:

patient level data are available upon request. Because WS is a rare disease, individuals may be identifiable from deep phenotyping description, especially those who exhibit uncommon individual or patterns of features.

Bibliography

  1. Cherniske EM, Carpenter TO, Klaiman C, Young E, Bregman J, Insogna K, Schultz RT, & Pober BR (2004, Dec 15). Multisystem study of 20 older adults with Williams syndrome. Am J Med Genet A, 131(3), 255–264. 10.1002/ajmg.a.30400 [DOI] [PubMed] [Google Scholar]
  2. Del Chierico F, Marzano V, Scanu M, Reddel S, Dentici ML, Capolino R, Di Donato M, Spasari I, Fiscarelli EV, Digilio MC, Abreu MT, Dallapiccola B, & Putignani L (2023, Jun 16). Analysis of gut microbiota in patients with Williams-Beuren Syndrome reveals dysbiosis linked to clinical manifestations. Sci Rep, 13(1), 9797. 10.1038/s41598-023-36704-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Deshpande AV, Oliver M, Yin M, Goh TH, & Hutson JM (2005, Dec). Severe colonic diverticulitis in an adolescent with Williams syndrome. J Paediatr Child Health, 41(12), 687–688. 10.1111/j.1440-1754.2005.00761.x [DOI] [PubMed] [Google Scholar]
  4. Garcia MA, Kling KM, Newbury RO, & Huang JS (2009, Feb). Complicated diverticular disease in a child with williams syndrome. J Pediatr Gastroenterol Nutr, 48(2), 233–236. 10.1097/MPG.0b013e31815c3b1b [DOI] [PubMed] [Google Scholar]
  5. Ghisleni C, Parma B, Cianci P, De Paoli A, Pangallo E, Agovino T, Cereda A, Bedeschi MF, Villa R, Fossati C, Modena P, Giudici C, Morando C, Memo L, Onesimo R, Zampino G, Salvatore S, Agosti M, & Selicorni A (2023, Jan). Celiac disease prevalence and predisposing-HLA in a cohort of 93 Williams-Beuren syndrome patients. Am J Med Genet A, 191(1), 84–89. 10.1002/ajmg.a.62990 [DOI] [PubMed] [Google Scholar]
  6. Howlin P, & Udwin O (2006, Feb). Outcome in adult life for people with Williams syndrome-- results from a survey of 239 families. J Intellect Disabil Res, 50(Pt 2), 151–160. 10.1111/j.1365-2788.2006.00775.x [DOI] [PubMed] [Google Scholar]
  7. Ignacio RC Jr., Klapheke WP, Stephen T, & Bond S (2012, Sep). Diverticulitis in a child with Williams syndrome: a case report and review of the literature. J Pediatr Surg, 47(9), E33–35. 10.1016/j.jpedsurg.2012.05.036 [DOI] [PubMed] [Google Scholar]
  8. Kozel BA, Barak B, Kim CA, Mervis CB, Osborne LR, Porter M, & Pober BR (2021, Jun 17). Williams syndrome. Nat Rev Dis Primers, 7(1), 42. 10.1038/s41572-021-00276-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Loffet EA, Durel JF, Gao J, Kam R, Lim H, & Nerurkar NL (2023, Dec). Elastic fibers define embryonic tissue stiffness to enable buckling morphogenesis of the small intestine. Biomaterials, 303, 122405. 10.1016/j.biomaterials.2023.122405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Morris CA (1993). Williams Syndrome. In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, & Amemiya A (Eds.), GeneReviews((R)). https://www.ncbi.nlm.nih.gov/pubmed/20301427 [Google Scholar]
  11. Morris CA, Braddock SR, & Council On G (2020, Feb). Health Care Supervision for Children With Williams Syndrome. Pediatrics, 145(2). 10.1542/peds.2019-3761 [DOI] [PubMed] [Google Scholar]
  12. Morris CA, Demsey SA, Leonard CO, Dilts C, & Blackburn BL (1988, Aug). Natural history of Williams syndrome: physical characteristics. J Pediatr, 113(2), 318–326. 10.1016/s0022-3476(88)80272-5 [DOI] [PubMed] [Google Scholar]
  13. Morris CA, Leonard CO, Dilts C, & Demsey SA (1990). Adults with Williams syndrome. Am J Med Genet Suppl, 6, 102–107. 10.1002/ajmg.1320370619 [DOI] [PubMed] [Google Scholar]
  14. Pai C, McIntosh BA, Knutsen RH, Levin MD, Tsang KM, Kozel BA, & Heuckeroth RO (2024, Jan). Loss of Baz1b in mice causes perinatal lethality, growth failure, and variable multi-system outcomes. Dev Biol, 505, 42–57. 10.1016/j.ydbio.2023.09.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pober BR (2010, Jan 21). Williams-Beuren syndrome. N Engl J Med, 362(3), 239–252. 10.1056/NEJMra0903074 [DOI] [PubMed] [Google Scholar]
  16. Renzi D, Stanley T, Waxler J, Lee H, Pober B, & Nordstrom M (2023). Body mass index variation in adults with Williams syndrome: associations with predicted dietary intake and food behaviors. Food Nutr Res, 67. 10.29219/fnr.v67.9321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Santer R, Pankau R, Schaub J, & Burgin-Wolff A (1996, Oct). Williams-Beuren syndrome and celiac disease. J Pediatr Gastroenterol Nutr, 23(3), 339–340. 10.1097/00005176-199610000-00029 [DOI] [PubMed] [Google Scholar]
  18. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, & Makharia GK (2018, Jun). Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 16(6), 823–836 e822. 10.1016/j.cgh.2017.06.037 [DOI] [PubMed] [Google Scholar]
  19. Staudt GE, & Eagle SS (2021, Jan). Anesthetic Considerations for Patients With Williams Syndrome. J Cardiothorac Vasc Anesth, 35(1), 176–186. 10.1053/j.jvca.2020.01.022 [DOI] [PubMed] [Google Scholar]
  20. Wessel A, Gravenhorst V, Buchhorn R, Gosch A, Partsch CJ, & Pankau R (2004, Jun 15). Risk of sudden death in the Williams-Beuren syndrome. Am J Med Genet A, 127A(3), 234–237. 10.1002/ajmg.a.30012 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supinfo

Data Availability Statement

patient level data are available upon request. Because WS is a rare disease, individuals may be identifiable from deep phenotyping description, especially those who exhibit uncommon individual or patterns of features.

RESOURCES